QQQ   399.03 (+0.30%)
AAPL   174.77 (+2.10%)
MSFT   332.95 (-0.59%)
FB   331.67 (+2.74%)
GOOGL   2,947.51 (+0.07%)
AMZN   3,525.25 (+0.06%)
TSLA   1,066.43 (+1.40%)
NVDA   318.13 (-1.89%)
BABA   125.77 (+0.18%)
NIO   35.03 (+5.77%)
CGC   11.01 (+3.48%)
AMD   144.67 (-0.12%)
GE   98.26 (+0.73%)
MU   85.80 (-0.03%)
T   23.13 (+0.22%)
F   19.83 (-0.65%)
DIS   153.60 (+1.85%)
PFE   51.49 (-0.44%)
AMC   32.68 (+5.28%)
ACB   6.64 (+4.08%)
BA   211.15 (+1.11%)
QQQ   399.03 (+0.30%)
AAPL   174.77 (+2.10%)
MSFT   332.95 (-0.59%)
FB   331.67 (+2.74%)
GOOGL   2,947.51 (+0.07%)
AMZN   3,525.25 (+0.06%)
TSLA   1,066.43 (+1.40%)
NVDA   318.13 (-1.89%)
BABA   125.77 (+0.18%)
NIO   35.03 (+5.77%)
CGC   11.01 (+3.48%)
AMD   144.67 (-0.12%)
GE   98.26 (+0.73%)
MU   85.80 (-0.03%)
T   23.13 (+0.22%)
F   19.83 (-0.65%)
DIS   153.60 (+1.85%)
PFE   51.49 (-0.44%)
AMC   32.68 (+5.28%)
ACB   6.64 (+4.08%)
BA   211.15 (+1.11%)
QQQ   399.03 (+0.30%)
AAPL   174.77 (+2.10%)
MSFT   332.95 (-0.59%)
FB   331.67 (+2.74%)
GOOGL   2,947.51 (+0.07%)
AMZN   3,525.25 (+0.06%)
TSLA   1,066.43 (+1.40%)
NVDA   318.13 (-1.89%)
BABA   125.77 (+0.18%)
NIO   35.03 (+5.77%)
CGC   11.01 (+3.48%)
AMD   144.67 (-0.12%)
GE   98.26 (+0.73%)
MU   85.80 (-0.03%)
T   23.13 (+0.22%)
F   19.83 (-0.65%)
DIS   153.60 (+1.85%)
PFE   51.49 (-0.44%)
AMC   32.68 (+5.28%)
ACB   6.64 (+4.08%)
BA   211.15 (+1.11%)
QQQ   399.03 (+0.30%)
AAPL   174.77 (+2.10%)
MSFT   332.95 (-0.59%)
FB   331.67 (+2.74%)
GOOGL   2,947.51 (+0.07%)
AMZN   3,525.25 (+0.06%)
TSLA   1,066.43 (+1.40%)
NVDA   318.13 (-1.89%)
BABA   125.77 (+0.18%)
NIO   35.03 (+5.77%)
CGC   11.01 (+3.48%)
AMD   144.67 (-0.12%)
GE   98.26 (+0.73%)
MU   85.80 (-0.03%)
T   23.13 (+0.22%)
F   19.83 (-0.65%)
DIS   153.60 (+1.85%)
PFE   51.49 (-0.44%)
AMC   32.68 (+5.28%)
ACB   6.64 (+4.08%)
BA   211.15 (+1.11%)
NASDAQ:RARE

Ultragenyx Pharmaceutical Stock Forecast, Price & News

$82.39
-2.05 (-2.43%)
(As of 12/8/2021 02:57 PM ET)
Add
Compare
Today's Range
$81.74
$84.57
50-Day Range
$73.71
$98.27
52-Week Range
$72.89
$179.65
Volume
5,233 shs
Average Volume
482,135 shs
Market Capitalization
$5.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.67
30 days | 90 days | 365 days | Advanced Chart
Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.


Ultragenyx Pharmaceutical logo

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RARE
Employees
893
Year Founded
N/A

Sales & Book Value

Annual Sales
$271.03 million
Book Value
$13.70 per share

Profitability

Net Income
$-186.57 million
Pretax Margin
-98.59%

Debt

Price-To-Earnings

Miscellaneous

Free Float
63,595,000
Market Cap
$5.62 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/08/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/10/2022

MarketRank

Overall MarketRank

2.29 out of 5 stars

Medical Sector

299th out of 1,394 stocks

Pharmaceutical Preparations Industry

131st out of 674 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

Is Ultragenyx Pharmaceutical a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ultragenyx Pharmaceutical stock.
View analyst ratings for Ultragenyx Pharmaceutical
or view top-rated stocks.

How has Ultragenyx Pharmaceutical's stock been impacted by Coronavirus?

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RARE shares have increased by 81.7% and is now trading at $82.39.
View which stocks have been most impacted by COVID-19
.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Ultragenyx Pharmaceutical
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.43) by $0.35. The biopharmaceutical company had revenue of $81.65 million for the quarter, compared to analysts' expectations of $78.16 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 38.25% and a negative net margin of 98.89%. During the same period in the prior year, the firm earned ($1.13) earnings per share.
View Ultragenyx Pharmaceutical's earnings history
.

What price target have analysts set for RARE?

15 brokerages have issued 1 year price objectives for Ultragenyx Pharmaceutical's stock. Their forecasts range from $73.00 to $179.00. On average, they expect Ultragenyx Pharmaceutical's stock price to reach $137.65 in the next twelve months. This suggests a possible upside of 67.1% from the stock's current price.
View analysts' price targets for Ultragenyx Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the following people:

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical CEO Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among Ultragenyx Pharmaceutical's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.06%), Capital Research Global Investors (4.93%), Wellington Management Group LLP (3.68%), Alliancebernstein L.P. (1.70%), Macquarie Group Ltd. (1.37%) and Bank of New York Mellon Corp (1.27%). Company insiders that own Ultragenyx Pharmaceutical stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends for Ultragenyx Pharmaceutical
.

Which institutional investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Millennium Management LLC, Renaissance Technologies LLC, Point72 Asset Management L.P., Two Sigma Investments LP, Morgan Stanley, Cubist Systematic Strategies LLC, and Goldman Sachs Group Inc.. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Camille L Bedrosian, Dennis Karl Huang, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, S Robson Walton, Theodore Alan Huizenga, Thomas Richard Kassberg, and William Aliski.
View insider buying and selling activity for Ultragenyx Pharmaceutical
or view top insider-selling stocks.

Which institutional investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Rock Springs Capital Management LP, Invesco Ltd., Janus Henderson Group PLC, Lord Abbett & CO. LLC, Dimensional Fund Advisors LP, Teachers Retirement System of The State of Kentucky, and International Biotechnology Trust PLC.
View insider buying and selling activity for Ultragenyx Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $82.39.

How much money does Ultragenyx Pharmaceutical make?

Ultragenyx Pharmaceutical has a market capitalization of $5.62 billion and generates $271.03 million in revenue each year. The biopharmaceutical company earns $-186.57 million in net income (profit) each year or ($5.29) on an earnings per share basis.

How many employees does Ultragenyx Pharmaceutical have?

Ultragenyx Pharmaceutical employs 893 workers across the globe.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

Where are Ultragenyx Pharmaceutical's headquarters?

Ultragenyx Pharmaceutical is headquartered at 60 Leveroni Court, Novato CA, 94949.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at [email protected], or via fax at 415-483-8810.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.